Defining long COVID using a population-based SARS-CoV-2 survey in California.

Autor: Pry JM; California Department of Public Health, Richmond, CA, USA; School of Medicine, University of California, Davis, CA, USA; Center for Infectious Disease Research in Zambia, Lusaka, Zambia. Electronic address: jmpry@ucdavis.edu., McCullough K; California Department of Public Health, Richmond, CA, USA., Lai KW; California Department of Public Health, Richmond, CA, USA., Lim E; California Department of Public Health, Richmond, CA, USA., Mehrotra ML; California Department of Public Health, Richmond, CA, USA., Lamba K; California Department of Public Health, Richmond, CA, USA., Jain S; California Department of Public Health, Richmond, CA, USA.
Jazyk: angličtina
Zdroj: Vaccine [Vaccine] 2024 Dec 02; Vol. 42 (26), pp. 126358. Date of Electronic Publication: 2024 Sep 17.
DOI: 10.1016/j.vaccine.2024.126358
Abstrakt: Background: More than four years after the start of the COVID-19 pandemic, understanding of SARS-CoV-2 burden and post-acute sequela of COVID (PASC), or long COVID, continues to evolve. However, prevalence estimates are disparate and uncertain. Leveraging survey responses from a large serosurveillance study, we assess prevalence estimates using five different long COVID definitions among California residents.
Methods: The California Department of Public Health (CDPH) conducted a cross-sectional survey that included questions about acute COVID-19 infection and recovery. A random selection of California households was invited to participate in a survey that included demographic information, clinical symptoms, and COVID-19 vaccination history. We assessed prevalence and predictors of long COVID among those previously testing positive for SARS-CoV-2 across different definitions using logistic regression.
Findings: A total of 2883 participants were included in this analysis; the majority identified as female (62.5 %), and the median age was 39 years (interquartile range: 17-55 years). We found a significant difference in long COVID prevalence across definitions with the highest prevalence observed when participants were asked about incomplete recovery (20.9 %, 95 % confidence interval [CI]: 19.4-22.5) and the lowest prevalence was associated with severe long COVID affecting an estimated 4.9 % (95 % CI 4.1-5.7) of the participant population. Individuals that completed the primary vaccination series had significantly lower prevalence of long COVID compared to those that did not receive COVID vaccination.
Interpretation: There were significant differences in the estimated prevalence of long COVID across different definitions. People who experience a severe initial COVID-19 infection should be considered at a higher probability for developing long COVID.
Funding: Centers for Disease Control and Prevention - Epidemiology and Laboratory Capacity.
Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
(Copyright © 2024 The Authors. Published by Elsevier Ltd.. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: